|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,008 DKK | -1.08% |
|
-2.43% | -6.82% |
| Apr. 16 | Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug | MT |
| Apr. 16 | Genmab A/S Announces DARZALEX Sales Results for the First Quarter of 2024 | CI |
Contact:
Corporate Vice President
Communications & Investor Relations
T: +1 609 524 0065
E: mmp@genmab.com
Investor
Senior Director
Investor Relations
T: +45 3377 9558
E: acn@genmab.com
Kalvebod Brygge 43
1560 Copenhagen V
WEB: www.genmab.com
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122
(C) 2021 Electronic News Publishing, source
| 1st Jan change | Capi. | |
|---|---|---|
| -6.82% | 18.79B | |
| -0.26% | 103B | |
| +3.60% | 96.73B | |
| +1.66% | 21.31B | |
| -16.19% | 21.21B | |
| -41.41% | 16.37B | |
| -22.96% | 13.68B | |
| +6.82% | 13.44B | |
| +22.25% | 10.98B | |
| -22.40% | 8.56B |
GENMAB A/S 
